Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 9/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.33 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30539887 | 0.87 | NLRP3 (0.53) | NLRP3JAK2NPC1RAB9ANOTUM | |
| SCHEMBL23037647 | 0.87 | NLRP3 (0.53) | NLRP3JAK2NPC1RAB9ANOTUM | |
| SCHEMBL29314845 | 0.85 | NLRP3 (0.52) | NLRP3JAK2NPC1RAB9ANOTUM | |
| SCHEMBL26785286 | 0.85 | NLRP3 (0.56) | NLRP3JAK2NPC1RAB9ANOTUM | |
| SCHEMBL27194823 | 0.77 | NLRP3 (0.49) | NLRP3JAK2NOTUM | |
| SCHEMBL29322759 | 0.74 | TLR8 (0.53) | NLRP3JAK2NPC1RAB9ANOTUM | |
| SCHEMBL26785249 | 0.74 | NLRP3 (0.54) | NLRP3JAK2CHEK1AKT1 | |
| SCHEMBL29322768 | 0.74 | NLRP3 (0.53) | NLRP3JAK2NPC1RAB9ANOTUM | |
| SCHEMBL23037612 | 0.74 | NLRP3 (0.56) | NLRP3JAK2NPC1RAB9ANOTUM | |
| SCHEMBL23037604 | 0.74 | NLRP3 (0.53) | NLRP3JAK2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | NLRP3 1/4885JAK2 3101/4885NPC1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.